RecruitingNot Applicable

Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia

Saudi Arabia77 participantsStarted 2025-03-10

Plain-language summary

This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment satisfaction as measured by the treatment satisfaction questionnaire for medication (TSQM) at week 24 among moderate to severe HS patients.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or Female adult patients ≥18 years of age at the time of data collection.
✓. Patient with a confirmed diagnosis of active moderate to severe HS.
✓. Secukinumab naive patients (first dose to coincide within one month of the signature of the informed consent) as per locally approved label.
✓. Patients can be using antibiotics or have undergone surgery as per routine clinical practice.
✓. Patients agree to sign an informed consent form (ICF) to be able to complete the questionnaires.

Exclusion criteria

✕. Patients not fulfilling any of the above-mentioned inclusion criteria.
✕. Patient's refusal to be included in the study or refusal to sign the ICF.
✕. A history of off-label indication uses of biological treatment or JAK inhibitor.

What they're measuring

Mean Score in the Treatment Satisfaction Questionnaire (TSQM)

Timeframe: Week 24

Trial details

NCT IDNCT06785779

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-09-30

Contact for this trial

Novartis Pharmaceuticals

+41613241111 novartis.email@novartis.com

View on ClinicalTrials.gov More Hidradenitis Suppurativa (HS) trials